These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 21247326)

  • 1. mTOR inhibitors and autosomal dominant polycystic kidney disease.
    Braun WE
    N Engl J Med; 2011 Jan; 364(3):287; author reply 287-8. PubMed ID: 21247326
    [No Abstract]   [Full Text] [Related]  

  • 2. mTOR inhibitors and autosomal dominant polycystic kidney disease.
    Levey AS; Stevens LA
    N Engl J Med; 2011 Jan; 364(3):287; author reply 287-9. PubMed ID: 21247327
    [No Abstract]   [Full Text] [Related]  

  • 3. mTOR inhibitors and autosomal dominant polycystic kidney disease.
    Grantham JJ; Bennett WM; Perrone RD
    N Engl J Med; 2011 Jan; 364(3):286-7; author reply 287-9. PubMed ID: 21247328
    [No Abstract]   [Full Text] [Related]  

  • 4. Everolimus in patients with autosomal dominant polycystic kidney disease.
    Walz G; Budde K; Mannaa M; Nürnberger J; Wanner C; Sommerer C; Kunzendorf U; Banas B; Hörl WH; Obermüller N; Arns W; Pavenstädt H; Gaedeke J; Büchert M; May C; Gschaidmeier H; Kramer S; Eckardt KU
    N Engl J Med; 2010 Aug; 363(9):830-40. PubMed ID: 20581392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease.
    Serra AL; Poster D; Kistler AD; Krauer F; Raina S; Young J; Rentsch KM; Spanaus KS; Senn O; Kristanto P; Scheffel H; Weishaupt D; Wüthrich RP
    N Engl J Med; 2010 Aug; 363(9):820-9. PubMed ID: 20581391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. mTOR inhibitors in polycystic kidney disease.
    Watnick T; Germino GG
    N Engl J Med; 2010 Aug; 363(9):879-81. PubMed ID: 20581393
    [No Abstract]   [Full Text] [Related]  

  • 7. Do mTOR inhibitors still have a future in ADPKD?
    Perico N; Remuzzi G
    Nat Rev Nephrol; 2010 Dec; 6(12):696-8. PubMed ID: 21109768
    [No Abstract]   [Full Text] [Related]  

  • 8. Efficacy and safety of mTOR inhibitor therapy in patients with early-stage autosomal dominant polycystic kidney disease: a meta-analysis of randomized controlled trials.
    He Q; Lin C; Ji S; Chen J
    Am J Med Sci; 2012 Dec; 344(6):491-7. PubMed ID: 22902868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autosomal dominant polycystic kidney disease and mTOR inhibitors: the narrow road between hope and disappointment.
    Ponticelli C; Locatelli F
    Nephrol Dial Transplant; 2010 Dec; 25(12):3809-12. PubMed ID: 20798121
    [No Abstract]   [Full Text] [Related]  

  • 10. [Autosomal dominant polycystic kidney disease].
    Horie S
    Nihon Jinzo Gakkai Shi; 2011; 53(1):6-9. PubMed ID: 21370570
    [No Abstract]   [Full Text] [Related]  

  • 11. Impact of mammalian target of rapamycin inhibition on autosomal-dominant polycystic kidney disease.
    Wüthrich RP; Kistler AD; Serra AL
    Transplant Proc; 2010 Nov; 42(9 Suppl):S44-6. PubMed ID: 21095452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sirolimus produced S-shaped effect on adult polycystic kidneys after 2-year treatment.
    Soliman A; Zamil S; Lotfy A; Ismail E
    Transplant Proc; 2012 Dec; 44(10):2936-9. PubMed ID: 23195001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-dose rapamycin (sirolimus) effects in autosomal dominant polycystic kidney disease: an open-label randomized controlled pilot study.
    Braun WE; Schold JD; Stephany BR; Spirko RA; Herts BR
    Clin J Am Soc Nephrol; 2014 May; 9(5):881-8. PubMed ID: 24721888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Sirolimus on Native Total Kidney Volume After Transplantation in Patients with Autosomal Dominant Polycystic Kidney Disease: A Randomized Controlled Pilot Study.
    Davis S; Gralla J; Chan L; Wiseman A; Edelstein CL
    Transplant Proc; 2018 Jun; 50(5):1243-1248. PubMed ID: 29880342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sirolimus therapy to halt the progression of ADPKD.
    Perico N; Antiga L; Caroli A; Ruggenenti P; Fasolini G; Cafaro M; Ondei P; Rubis N; Diadei O; Gherardi G; Prandini S; Panozo A; Bravo RF; Carminati S; De Leon FR; Gaspari F; Cortinovis M; Motterlini N; Ene-Iordache B; Remuzzi A; Remuzzi G
    J Am Soc Nephrol; 2010 Jun; 21(6):1031-40. PubMed ID: 20466742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sirolimus attenuates disease progression in an orthologous mouse model of human autosomal dominant polycystic kidney disease.
    Zafar I; Ravichandran K; Belibi FA; Doctor RB; Edelstein CL
    Kidney Int; 2010 Oct; 78(8):754-61. PubMed ID: 20686448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of mammalian target of rapamycin inhibitors in patient with autosomal dominant polycystic kidney disease: an updated meta-analysis.
    Lin CH; Chao CT; Wu MY; Lo WC; Lin TC; Wu MS
    Int Urol Nephrol; 2019 Nov; 51(11):2015-2025. PubMed ID: 31578673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pulsed oral sirolimus in advanced autosomal-dominant polycystic kidney disease (Vienna RAP Study): study protocol for a randomized controlled trial.
    Riegersperger M; Herkner H; Sunder-Plassmann G
    Trials; 2015 Apr; 16():182. PubMed ID: 25899445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Everolimus does not further reduce polycystic liver volume when added to long acting octreotide: results from a randomized controlled trial.
    Chrispijn M; Gevers TJ; Hol JC; Monshouwer R; Dekker HM; Drenth JP
    J Hepatol; 2013 Jul; 59(1):153-9. PubMed ID: 23499726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological management of polycystic kidney disease.
    Wüthrich RP; Mei C
    Expert Opin Pharmacother; 2014 Jun; 15(8):1085-95. PubMed ID: 24673552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.